MITSUBISHI TANABE PHARMA CORPORATION

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy

Phase 2

Completed

Conditions: Diabetic Polyneuropathy

Interventions: Drug: MCC-257
Drug: Placebo

First Posted Date: 2006-03-28

Last Posted Date: 2007-12-28

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 420

Registration Number: NCT00307749

Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C

Phase 3

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Ursodeoxycholic acid 150mg / day
Drug: Ursodeoxycholic acid 600mg / day
Drug: Ursodeoxycholic acid 900mg / day

First Posted Date: 2005-09-20

Last Posted Date: 2012-03-12

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 596

Registration Number: NCT00200343

Locations: 🇯🇵
Department of Gastroenterology, University of Tokyo, hongo, bunkyo-ku, Tokyo, Japan

Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke

Phase 4

Completed

Conditions: Cerebral Infarction

Interventions: Drug: Edaravone
Drug: Sodium Ozagrel

First Posted Date: 2005-09-20

Last Posted Date: 2013-01-15

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 401

Registration Number: NCT00200356

Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study

Phase 3

Completed

Conditions: Cerebral Infarction

Interventions: Drug: MCI-9042

First Posted Date: 2005-09-07

Last Posted Date: 2015-04-10

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 46

Registration Number: NCT00147303

Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke

Phase 3

Completed

Conditions: Cerebral Infarction
Brain Ischemia

Interventions: Drug: Alteplase

First Posted Date: 2005-09-07

Last Posted Date: 2012-03-01

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 103

Registration Number: NCT00147316

Locations: 🇯🇵
National Cardiovascular Center, Suita, Osaka, Japan

Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)

Phase 3

Completed

Conditions: Cerebral Infarction

Interventions: Drug: MCI-9042
Drug: Aspirin

First Posted Date: 2005-08-12

Last Posted Date: 2008-08-19

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 1510

Registration Number: NCT00129805

MCC-135 as Adjunct Therapy to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction Patients

Phase 2

Completed

Conditions: Myocardial Infarction

First Posted Date: 2004-02-18

Last Posted Date: 2005-06-24

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 414

Registration Number: NCT00078013

Locations: 🇺🇸
Massachusetts General Hospital/ Harvard Medical School, Boston, Massachusetts, United States

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

Phase 3

Completed

Conditions: Peripheral Vascular Disease

First Posted Date: 2003-05-02

Last Posted Date: 2006-05-19

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 280

Registration Number: NCT00059657

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

Phase 3

Terminated

Conditions: Peripheral Vascular Disease

First Posted Date: 2003-05-02

Last Posted Date: 2005-06-24

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 560

Registration Number: NCT00059644

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy